SF3B1 and myelodysplastic syndrome: Overall, these findings support that SF3B1 mutations in MDS may lead to erythroid defects such as erythrocyte apoptosis, erythrocyte cycle arrest, and delayed erythrocyte differentiation (23, 32, 42, 44), explaining the clinical features of anemia seen more frequently in MDS patients.